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Glutamine is an important amino acid 
from a metabolic point of view. As an 
amino acid and a precursor for other 
amino acids, it sustains protein synthesis. 
It is also required for production of nucle-
otides (pyrimidines) and α-ketoglutarate 
(αKG). αKG is produced via double 
deamination of glutamine, a process 
termed glutaminolysis. Glutamine is first 
de-aminated by glutaminase (GLS) to 
produce glutamate. Glutamate is then 
converted to αKG by glutamate dehydro-
genase (GDH). The production of αKG 
from glutamine is critical to replenish the 
tricarboxylic acid (TCA) cycle and thus to 
sustain ATP levels. The metabolic impor-
tance of glutamine is also reflected in the 
fact that cancer cells are often glutamine 
addicted. Intriguingly, the catabolism 
of glutamine by cancer cells exceeds the 
cellular requirement for glutamine in 
the production of amino acids, nucleo-
tides and energy. What else is glutamine 
used for that could explain the glutamine 
addiction of cancer cells? Recent findings 
by Durán et al. demonstrate that gluta-
minolysis activates mammalian target 
of rapamycin (mTOR), hence inhibiting 
autophagy and promoting cell growth.1 
This suggests that glutamine metabolism 
is additionally required as part of a signal-
ing process to upregulate cell growth and 
proliferation.
TOR is a conserved serine/threo-
nine kinase that regulates cell growth, 
metabolism and aging.2,3 It forms two 
structurally and functionally distinct 
complexes termed TORC1 and TORC2 
(mTORC1 and mTORC2 in mammals). 
While mTORC1 is activated by nutrients 
(amino acids), growth factors and cellular 
energy, mTORC2 is activated by growth 
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factors alone. Of note, among the amino 
acids, leucine is the most effective activa-
tor of mTORC1.4 While the mechanism 
by which leucine activates mTORC1 has 
been investigated for many years, the study 
by Durán et al.1 suggests leucine activates 
mTORC1 through its role as an activator 
of glutaminolysis. Leucine is an allosteric 
activator of GDH. By directly binding to 
GDH, leucine stimulates de-amination of 
glutamate to form αKG. αKG, in turn, 
activates mTORC1 via activation of prolyl 
hydroxylases,5 a family of αKG-dependent 
dioxygenases. Importantly, this provides 
a mechanism by which mTORC1 senses 
leucine. The activation of GDH by leu-
cine is also known to play a role in insulin 
secretion in pancreatic β cells. Thus, the 
findings of Durán et al.1 also suggest that 
mTORC1 may mediate leucine-depen-
dent stimulation of insulin secretion.
Activation of mTORC1 by glutaminol-
ysis provides an explanation for why glu-
tamine metabolism in tumor cells exceeds 
the need for glutamine as a biosynthetic 
precursor. mTORC1 activation is neces-
sary for protein synthesis, nutrient uptake 
and cell growth. Indeed, mTORC1 is 
upregulated in a broad variety of can-
cers.6 Durán et al.1 suggest that upregu-
lation of glutaminolysis in cancer cells 
ensures mTORC1 activation to sustain 
cell growth. This model also suggests that 
glutamine-addicted cancer cells might be 
particularly sensitive to rapamycin.
Neomorphic mutations in the enzyme 
isocitrate dehydrogenase 1 (IDH1), 
which are found in gliomas and acute 
myelogenous leukemia, are associated 
with glutamine addiction.7 The onco-
genic versions of IDH1 convert αKG to 
the oncometabolite 2-hydroxyglutarate 
(2-HG). The mechanism by which 2-HG 
promotes tumorigenesis is currently under 
intensive investigation. A recent study 
using cultured human astrocytes sug-
gests that 2-HG may be a particularly 
effective activator of prolyl hydroxylases.8 
Hyperactivation of prolyl hydroxylases by 
2-HG may, in turn, lead to hyperactiva-
tion of mTORC1. However, in vivo stud-
ies using knock-in mice suggest that 2-HG 
prevents activation of prolyl hydroxylases,9 
and a role of mTORC1 in 2-HG-mediated 
tumorigenesis remains to be investigated.
Future strategies targeting both glu-
tamine metabolism and mTOR sig-
naling might show synergistic effects 
against cell growth and proliferation in 
glutamine-addicted cancer cells. Further 
work will help to elucidate the therapeu-
tic repercussion of the recently discov-
ered link between glutamine metabolism 
and mTORC1. Certainly, the findings of 
Durán et al.1 are an example of crosstalk 
between metabolism and cell signaling, 
and may provide new approaches for the 
design of targeted therapies against cancer.
Glutaminolysis, via activation of 
mTORC1, also inhibits autophagy and 
increases cell size. The inhibition of 
autophagy by glutaminolysis prevents 
the needless production of excess energy 
derived from recycling cellular compo-
nents. Conversely, a lack of glutaminoly-
sis inhibits mTORC1, hence activating 
autophagy. In this case, autophagy is an 
alternative means of obtaining nutrients 
and energy when the TCA cycle is not 
sustained by glutaminolysis. αKG produc-
tion through glutaminolysis is the major 
anaplerotic reaction maintaining the TCA 
cycle. Thus, controlling mTORC1 and 
autophagy via glutaminolysis ensures that 
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the cell coordinates energetic demand and 
nutrient availability.
In agreement with Durán et al.,1 van 
der Vos et al.10 recently reported that an 
increase in glutamine synthetase (which 
catalyzes the reaction opposite to that of 
GLS, producing glutamine from gluta-
mate) inhibits mTORC1 and activates 
autophagy. Thus, mTORC1 appears to 
sense the flux between glutamine and αKG 
in both directions. When flux is toward 
αKG production, mTORC1 is activated to 
inhibit autophagy. Conversely, mTORC1 
is inactivated when flux is toward gluta-
mine production, enabling autophagy to 
provide nutrients and energy. However, 
flux toward glutamine synthesis may 
have physiological relevance only in cer-
tain conditions. Most mammalian tissues 
express low levels of glutamine synthetase, 
with liver being a notable exception.
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